The First International HPV Vaccine Information Clearinghouse
Roche.com
Basel, 11 April 2007
Roche to develop and commercialize products from Transgene’s programme.
Roche and Transgene announced today that they have entered into an exclusive worldwide collaboration agreement to develop and commercialize products from Transgene’s therapeutic vaccine program against Human Papilloma Virus-mediated diseases.
PubMed.gov
Clin Vaccine Immunol. 2010 Jul 28. [Epub ahead of print]
Human papillomavirus (HPV) 58 exists in a relatively high prevalence in certain parts of the world including East Asia. This study examined T-cell response to HPV 58 L1, E6 and E7 peptides among women with cleared infection, cervical intraepithelial neoplasia (CIN) grade 2 and 3, and invasive cervical cancer (ICC).
American College of Obstetrics and Gynecology
July 2010
Mark Schiffman, MD, MPH, and Nicolas Wentzensen, MD, PhD
Cervical cancer is one of the most common female
malignancies worldwide; 80% of cases occur in
low-resource regions.1,2 Screening programs have been
very successful in the United States, Europe, and other
regions able to achieve broad and sustained coverage. In
the United States, the disease is controlled at an annual
cost of billions of dollars representing a major commitment
by patients and clinicians.
American College of Obstetrics and Gynecology
July 2010
Channa E. Schmeink, MD, Leon F. Massuger, MD, PhD, Charlotte H. Lenselink, MD, PhD, Wim G. Quint, PhD, Willem J. Melchers, PhD, and Ruud L. Bekkers, MD, PhD
OBJECTIVE: To estimate the effect of the menstrual cycle
and oral contraceptive pill (OCP) use on the prevalence,
incidence, and persistence of human papillomavirus.
